MedTrace Logo

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-09-28

No results posted yet for this study

Summary

The most common reason for contact lens discontinuation is contact lens discomfort. The investigators believe that inflammation plays a role in contact lens discomfort and the use of lifitegrast 5% ophthalmic solution may reduce end of the day contact lens discomfort. This study will enroll 21 contact lens users who will be receiving lifitegrast 5% ophthalmic solution and monitor the contact lens discomfort for a 8 week period while.

Conditions

  • Contact Lens
  • Contact Lens Discomfort
  • Contact Lens Dryness

Interventions

DRUG

Lifitegrast

Lifitegrast used twice a day

Sponsors & Collaborators

  • EV Clinical Trials

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-16
Primary Completion
2017-07-14
Completion
2017-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03686878 on ClinicalTrials.gov